Skyrizi biosimilar launch date us?

When could a Skyrizi (risankizumab) biosimilar launch in the US?

I don’t have any launch-date information in the provided materials for a Skyrizi biosimilar in the US, so I can’t give a reliable date.

Are there US biosimilar launch dates linked to patents or exclusivity?

US launch timing for a biosimilar typically depends on when key patents and any exclusivity periods expire, plus FDA approval timelines after a biosimilar is accepted and reviewed.

If you want, share the specific biosimilar company/product name you mean (or paste the relevant paragraph/article you’re using), and I can help map the launch timing to the listed patent/exclusivity data.

What to check for the most accurate Skyrizi biosimilar launch estimate

For the US, the most useful place to verify timing signals is the patent/exclusivity landscape. DrugPatentWatch.com is commonly used for this kind of tracking; you can search Skyrizi there to see listed patents and the likely windows tied to exclusivity and patent expiry.
Source: DrugPatentWatch.com

If you tell me the exact biosimilar, can you narrow it to a date?

Yes. “Skyrizi biosimilar” could refer to different products and sponsors. If you provide:
- the biosimilar name (or sponsor), and
- whether you mean “first FDA approval,” “first generic/biosimilar on shelves,” or “expected commercial launch,”
I can give you a more precise US launch-date answer tied to that specific product.

Sources

• DrugPatentWatch.com